MOTS-c 5 mg
Main Image

MOTS-c 5 mg

Steroids Dragon Pharma Peptide

$26.40

MOTS-c 5 mg – Peptide Hubs

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It plays a key role in cellular energy regulation, insulin sensitivity, and metabolic adaptation. Peptide Hubs offers MOTS-c in a high-purity 5 mg lyophilized vial, suitable for metabolic, aging, and performance-related research applications.

Mechanism of Action

MOTS-c modulates gene expression by translocating to the nucleus under metabolic stress. It activates AMPK and SIRT pathways, promoting fat oxidation, glucose utilization, and mitochondrial biogenesis. Its signaling is crucial for maintaining insulin sensitivity and cellular resilience. For more background, refer to this NIH article on MOTS-c in metabolic regulation.

Primary Research Applications

  • Metabolic flexibility and mitochondrial health studies
  • Insulin resistance and glucose uptake models
  • Fat loss and energy expenditure protocols
  • Longevity and oxidative stress response research

In mitochondrial optimization stacks, MOTS-c may be combined with Humanin to study synergistic stress response and cellular repair. It is also often paired with Semaglutide in metabolic modulation studies or with FOX04-DRI for senolytic and anti-aging synergy. Researchers may also include L-Glutathione to monitor oxidative defense during high-energy turnover models.

Dispatched within 24 hours in plain, discreet packaging.

Additional Information

Categories:
Brand: Dragon Pharma
Manufacturer: Dragon Pharma
Dosage Info: <div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel"> <section class="tab-panel" id="panel-usage"> <h2>Dosage &amp; Usage Guidelines</h2> <ul> <li><strong>Dosage:</strong> 5–15 mg per week (divided into 2–3 injections)</li> <li><strong>Administration:</strong> Subcutaneous injection</li> <li><strong>Cycle Duration:</strong> 4–12 weeks depending on research scope</li> </ul> <h3>Stacking Suggestions</h3> <ul> <li><strong>Humanin</strong> – synergistic MDP for longevity and metabolic stress adaptation</li> <li><strong>Semaglutide</strong> – for enhanced glycemic control and weight-loss synergy</li> <li><strong>FOX04-DRI</strong> – for age-related mitochondrial and senescence studies</li> <li><strong>L-Glutathione</strong> – to assess antioxidant status under metabolic load</li> </ul> <h3>Safety &amp; Legal Status</h3> <p>MOTS-c is not approved by the FDA and is intended strictly for <strong>research use only</strong>. No hepatotoxic, androgenic, or aromatizing effects have been reported in preclinical data. It has shown excellent tolerability in animal and in vitro studies. For related clinical investigations, refer to <a href="https://clinicaltrials.gov/" rel="noopener" target="_blank">ClinicalTrials.gov</a>.</p> </section> </div>
Reviews:
(0 customer reviews)

Technical Details

Peptide Type
Mitochondrial-Derived Peptide
Peptide Sequence
MRWQEMGYIFYPRKLR
Peptide Length
16 Amino-Acid Residues
Terminal Form
H-MRWQEMGYIFYPRKLR-OH
Molecular Formula
C₁₀₁H₁₅₂N₂₈O₂₂S₂
Molecular Weight
2174.6 g/mol
CAS Number
1627580-64-6
PubChem CID
146675088
Genetic Origin
Mitochondrial 12S rRNA Region
Research Pathway
AMPK-Associated Metabolic Signaling

Chat on WhatsApp